Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Trial source : Www.celyad.com save search
Celyad Oncology Announces First Patient Dosed in KEYNOTE-B79 Phase 1b Trial
Published: 2021-12-16 (Crawled : 07:00) - celyad.com
CYAD | $0.47 -12.49% 49K
|
Health Technology
|
| O: 2.91%
H: 0.0%
C: -1.88%
phase 1b trial cel phase 1 phase 2b
Celyad Oncology Presents Preclinical Data on Allogeneic CAR T Therapy Program and Highlights KEYNOTE-B79 Clinical Trial Design at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
Published: 2021-11-12 (Crawled : 12:15) - celyad.com
CYAD | $0.47 -12.49% 49K
|
Health Technology
|
| O: -0.74%
H: 0.0%
C: 0.0%
immunotherapy therapy cancer trial car-t preclinical pre-clinical designation
Celyad Oncology to Present Data from Phase 1 IMMUNICY-1 Trial of Non-Gene Edited Allogeneic CAR T Candidate CYAD-211 in Relapsed/Refractory Multiple Myeloma at the European Hematology Association Virtual Congress
Published: 2021-05-12 (Crawled : 20:00) - celyad.com
CYAD | $0.47 -12.49% 49K
|
Health Technology
|
| O: 11.11%
H: 1.69%
C: -2.71%
europe phase 1 trial phase 3 phase 2 car-t
Gainers vs Losers
| 70% | 30% |
Top 10 Gainers
AGBA | News | $1.305 226.25% 130M
|
Finance
EGOX | $0.0503 39.72% 320M
|
RWOD | $10.52 31.56% 5.9M
|
n/a
ZCMD | $1.905 31.38% 30M
|
Commercial Services
MRDB 4 | $0.536 27.65% 2M
|
n/a
BSFC | $0.0822 27.64% 75M
|
Manufacturing
TPET | $0.4121 25.68% 45M
|
n/a
NVFY | $2.65 25.59% 33M
|
Consumer Durables
INDO | $5.1 25.0% 15M
|
Energy Minerals
AULT | $0.2998 23.83% 53M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.